Johnson & Johnson (JNJ)
NYSE: JNJ · Real-Time Price · USD
156.12
+1.66 (1.07%)
May 2, 2025, 4:00 PM EDT - Market closed
Johnson & Johnson Employees
Johnson & Johnson had 138,100 employees as of December 29, 2024. The number of employees increased by 6,200 or 4.70% compared to the previous year.
Employees
138,100
Change (1Y)
6,200
Growth (1Y)
4.70%
Revenue / Employee
$646,857
Profits / Employee
$157,929
Market Cap
375.64B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 29, 2024 | 138,100 | 6,200 | 4.70% |
Dec 31, 2023 | 131,900 | -20,800 | -13.62% |
Jan 1, 2023 | 152,700 | 11,000 | 7.76% |
Jan 2, 2022 | 141,700 | 7,200 | 5.35% |
Jan 3, 2021 | 134,500 | 2,300 | 1.74% |
Dec 29, 2019 | Pro | Pro | Pro |
Dec 30, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Jan 1, 2017 | Pro | Pro | Pro |
Jan 3, 2016 | Pro | Pro | Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
Eli Lilly and Company | 47,000 |
JNJ News
- 1 day ago - Dogs Of The Dow Chase May's 'Safer' Buy - Seeking Alpha
- 2 days ago - J&J-backed HistoSonics explores sale at $2.5 billion valuation, FT reports - Reuters
- 4 days ago - Healthy Returns: Here are the drugmakers with new U.S. investments as Trump's pharma tariffs loom - CNBC
- 4 days ago - FDA Approves Johnson & Johnson's IMAAVYTM (nipocalimab-aahu) a New Treatment for Myasthenia Gravis (MG), Offering Hope for Families - GlobeNewsWire
- 4 days ago - US FDA approves J&J's immune disorder drug - Reuters
- 4 days ago - Johnson & Johnson receives FDA approval for IMAAVY™ (nipocalimab-aahu), a new FcRn blocker offering long-lasting disease control in the broadest population of people living with generalized myasthenia gravis (gMG) - PRNewsWire
- 4 days ago - Best Dividend Aristocrats For May 2025 - Seeking Alpha
- 5 days ago - Trump to tout US investments from Nvidia, J&J, Hyundai, Toyota - Reuters